Cold Agglutinin Disease Market: Current Analysis and Forecast (2023-2030)
Emphasis on Drugs (Corticosteroids, Alkylating Agents, Purine Nucleoside Analogs, Biologics, and Others); Route of Administration (Oral, Parenteral, and Others); End-User (Hospitals, Specialty Clinics, and Others); Region/Country
The cold agglutinin disease market is expected to grow at a strong CAGR of around 18% during the forecast period owing to the rising research and development activities aiding in cold agglutinin disease, and the rising geriatric population globally. For instance, according to the report of the U.S. Census Bureau in 2021, more than 54 million people of geriatric age were living in the country in 2020 and this number is expected to reach 85.7 million by 2050, which will be about 20% of the total population of the U.S. In addition to this, the increasing clinical trials by pharmaceutical companies to find a cure for auto-immune diseases are also driving the cold agglutinin disease market. Global pharmaceutical giants are leaving no stone unturned to showcase their potential. For instance, Bioverativ, a Sanofi company started a clinical trial in March 2021 with the objective of assessing the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088.
Some of the major players operating in the market include Johnson & Johnson Services, Inc., Novartis AG; Bayer AG; Pfizer Inc.; Sanofi; AstraZeneca; Bristol-Myers Squibb Company; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; GSK plc.
Insights Presented in the Report
“Amongst drugs, the biologics category to grow with high CAGR during the forecast period”
Based on drugs, the market is segmented into corticosteroids, alkylating agents, purine nucleoside analogs, biologics, and others. The biologics segment is expected to hold a significant share in the forecast period owing to its revolutionizing treatment of various chronic diseases, including cancer, autoimmune disorders, and inflammatory conditions. Biologics are designed to target specific molecules or cells, which can lead to more effective and efficient treatment. They can also be tailored to individual patients based on their unique genetic profiles, allowing for more personalized treatment. Additionally, they have been shown to improve survival rates in certain types of diseases. For instance, Top of FormNovartis International AG announced in September 2020 that it had initiated a phase III clinical study to evaluate the safety and efficacy of crizanlizumab, which is a humanized monoclonal antibody in adult patients with cold agglutinin disease. Thus, amongst drugs, the biologics category is expected to grow with a high CAGR during the forecast period.
“Amongst routes of administration, the parenteral segment held a significant share in the year 2022”
By the route of administration, the market is bifurcated into oral, parenteral, and others. The parenteral segment held a significant share in 2022 majorly due to the advances in technology, increased awareness of the medical condition, and an aging population are all factors that have contributed to this development. For example, in January 2020, a clinical phase I study was initiated by Apellis Pharma, Inc. to evaluate the safety, tolerability, and pharmacokinetics of pegcetacoplan subcutaneously in the treatment of cold agglutin disease. Thus, the parenteral segment dominated the market in the year 2022 amongst routes of administration.
“Amongst end-users, the specialty clinics segment to grow with a significant rate in forecast period”
Based on end-users, the market is segmented into hospitals, specialty clinics, and others. The specialty clinic segment is expected to grow with high CAGR owing to the growth of healthcare systems, as well as the rise in the incidence and prevalence of cold agglutinins and cardiovascular diseases associated with them. Also, several new launches and programs for providing enhanced care to patients are driving this segment’s growth. A prime example of this is the launch of the Walgreens Find Care specialty pharmacy program in June 2020 by Walgreens Boots Alliance, which is intended to provide individualized care to those with rare and chronic conditions, such as cold agglutinin disease. Thus, amongst end-users, the specialty clinics segment is expected to grow at a significant rate in the forecast period.
Cold Agglutinin Disease Market Report Coverage
“Amongst regions, North America region held a significant share in the year 2022”
For a better understanding of the market adoption of the cold agglutinin disease industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of cold agglutinin disease in 2022. Several factors such as an increase in the incidence of cold agglutinin, an increase in the demand for non-hazardous medical devices, an increase in government attention to the sector, an increase in chronic diseases, a surge in government investment in expanding healthcare facilities, and the implementation of regulatory reforms. For instance, U.S-based Incyte Corporation started a clinical trial in March 2022 with the objective of studying the efficacy and safety of parsaclisib in participants with primary warm autoimmune hemolytic anemia which is a rare, acquired condition caused by autoantibody- and complement-mediated hemolysis of red blood cells and typically presents as cold agglutinin disease. Thus, North America dominated the cold agglutinin disease market among regions in the year 2022.
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The global cold agglutinin disease market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Cold Agglutinin Disease Market Analysis (2023-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global cold agglutinin disease market were the three major steps undertaken to create and analyze the adoption of cold agglutinin disease in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global cold agglutinin disease market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the cold agglutinin disease market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the cold agglutinin disease market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments and sub-segments for major regions. Major segments are included in the report as drugs, route of administration, end-users, and region. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the cold agglutinin disease market. Further, we conducted factor analysis using dependent and independent variables such as drugs, route of administration, end-users, and region of the cold agglutinin disease market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the cold agglutinin disease market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global cold agglutinin disease market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the cold agglutinin disease market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the global cold agglutinin disease market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global cold agglutinin disease market. data was split into several segments & sub-segments post studying various parameters and trends in the areas of the drugs, route of administration, end-users, and region in the global cold agglutinin disease market.
The main objective of the Global Cold Agglutinin Disease Market Study
The current & future market trends of the global cold agglutinin disease market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the cold agglutinin disease market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
- Segments in the study include areas of drugs, route of administration, end-users, and region Define and analyze the regulatory framework for the cold agglutinin disease industry
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry
- Analyze the current and forecast market size of the cold agglutinin disease market for the major region
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
- Company profiles of the cold agglutinin disease market and the growth strategies adopted by the market players to sustain in the fast-growing market
- Deep dive regional level analysis of the industry
Frequently Asked Questions FAQs
Q1: What is the cold agglutinin disease market's current market size and growth potential?
Q2: What are the driving factors for the growth of the cold agglutinin disease market?
Q3: Which segment has the largest share of the cold agglutinin disease market by drugs?
Q4: Which region will dominate the cold agglutinin disease market?
Q5: Who are the key players operating in the cold agglutinin disease market?
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
